Form DRS - Draft Registration Statement:
SEC Accession No. 0000950123-20-003618
Filing Date
2020-04-27
Accepted
2020-04-27 17:26:39
Documents
8

Document Format Files

Seq Description Document Type Size
1 filename1.htm DRS 1028216
2 GRAPHIC g844461g00s01.jpg GRAPHIC 55332
3 GRAPHIC g844461g29d22.jpg GRAPHIC 53235
4 GRAPHIC g844461g44l68.jpg GRAPHIC 158651
5 GRAPHIC g844461g47g79.jpg GRAPHIC 51556
6 GRAPHIC g844461g64b64.jpg GRAPHIC 100708
7 GRAPHIC g844461g71p99.jpg GRAPHIC 50472
8 GRAPHIC g844461g79w00.jpg GRAPHIC 101914
  Complete submission text file 0000950123-20-003618.txt   1817941
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

EIN.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DRS | Act: 33 | File No.: 377-03142 | Film No.: 20821296
SIC: 2836 Biological Products, (No Diagnostic Substances)